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Low serum 25-hydroxyvitamin D (25(OH)D) concentration has been often 
reported in obese human. Lifestyle factors such as inadequate sun exposure 
and physiological factors such as impaired hepatic 25-hydroxylation have 
been suggested as possible explanations for vitamin D deficiency in obesity, 
however, the precise mechanism has not been elucidated. We investigated 
the effects of obesity on vitamin D status and the expression of vitamin D 
metabolizing enzymes using high fat diet-induced obese mice in order to 
understand the underlying mechanisms of altered vitamin D metabolism as-
sociated with obesity. Four-wk-old C57BL/6 mice were fed control diet con-
taining 10% energy fat (control group) or high fat diet with 45% energy fat 




concentration between groups while serum 1,25-dihydroxyvitamin D 
(1,25(OH)2D) concentration was significantly higher in obese mice. Hepatic 
mRNA levels of 25-hydroxylases (Cyp2r1, Cyp27a1 and Cyp2j3) were low-
er in obese group, but CYP27A1 protein expression did not differ between 
groups. Renal 1α-hydroxylase (Cyp27b1) mRNA level was upregulated and 
24-hydroxylase (Cyp24) mRNA level was downregulated in obese group. 
Serum 1,25(OH)2D concentration correlated positively with renal Cyp27b1 
expression level and negatively with renal Cyp24 expression level. No dif-
ference in serum calcium level was observed between groups, but serum 
parathyroid hormone (PTH) concentration was higher in obese mice. Serum 
concentration of PTH correlated positively with body weight. In visceral 
adipose tissue, mRNA levels of 25-hydroxylases, Cyp27a1 and Cyp2j3, and 
vitamin D receptor (Vdr) were higher in obese mice. Overall, the expression 
of vitamin D metabolizing enzymes was influenced by high fat diet-induced 
obesity, which might partly explain the mechanisms of altered vitamin D 
endocrine system in obesity. Higher concentration of serum PTH and 
1,25(OH)2D in obese mice suggests abnormal regulation of serum 
1,25(OH)2D concentrations by secondary hyperparathyroidism, which might 
have contributed to lower hepatic 25-hydroxylase mRNA levels. Higher 




enhanced nonclassic functions by the interaction between 1,25(OH)2D and 
VDR in adipose tissue.  
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I.  Introduction 
It has been observed that obese subjects are more likely to have vitamin D 
deficiency (serum 25(OH)D concentration below 20 ng/mL) or insufficiency 
(serum 25(OH)D concentration between 21 and 29 ng/mL) (Earthman et al., 
2012). An inverse relationship between body mass index (BMI) and serum 
25(OH)D has been reported in obese human (Cheng et al., 2010, Drincic et 
al., 2012, Looker, 2005). In addition, an increase in serum 25(OH)D after 
significant weight loss following bariatric surgery was observed in obese 
patients who had low preoperative levels of serum 25(OH)D (Compher et 
al., 2008). 
Various explanations suggested for low 25(OH)D status associated with 
obesity were limited exposure to the sun light due to decreased activity and 
sequestration of vitamin D3 in adipose tissue (Earthman et al., 2012). Re-
cently, challenging the sequestration hypothesis, simple volumetric 
dilutional model was suggested as another explanation (Drincic et al., 2012). 
An impaired hepatic synthesis of 25(OH)D attributed to elevated levels of 
1,25(OH)2D and PTH was also suggested as a reason for low 25(OH)D sta-
tus in obesity (Bell et al., 1985, Bell et al., 1984). Obese human was shown 
to have higher PTH and 1,25(OH)2D levels and lower 25(OH)D level (Bell 
et al., 1985). And, 1,25(OH)2D was suggested to inhibit hepatic synthesis of 
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25(OH)D as administration of 1,25(OH)2D in normal subjects prevented the 
increase in serum 25(OH)D in response to 2.5 mg of vitamin D challenge 
(Bell et al., 1984). However, the precise mechanism for low 25(OH)D status 
associated with obesity is still not clear.  
Vitamin D metabolism mainly consists of hydroxylations at three differ-
ent positions (1, 25, and 24) by hydroxylases that function coordinately to 
metabolize vitamin D and its metabolites. Once vitamin D is formed in skin 
via UV-light dependent reaction or obtained from the diet, it is transported 
in circulation to the liver where it is converted to 25(OH)D by 25-
hydroxylases including CYP2R1, CYP27A1, and CYP2J3. The major circu-
lating form of vitamin D, 25(OH)D, is further hydroxylated by 1α-
hydroxylase (CYP27B1) in the kidney to the hormonally active 1,25(OH)2D. 
25(OH)D and 1,25(OH)2D can be catabolized by 24-hydroxylase (CYP24) 
(Jones et al., 2012). 1,25(OH)2D exerts its classical functions related to bone 
mineral homeostasis by binding to the vitamin D receptor (VDR) in the gut 
and kidney, but, expression of VDR has been also reported in other tissues 
including adipose tissue which suggests the diverse effects of vitamin D be-
yond its classical roles in bone metabolism (Bikle, 2009). In addition, the 
expression of vitamin D metabolizing enzymes was observed and the pres-
ence of local vitamin D metabolism was suggested in human adipose tissue 
(Wamberg et al., 2013). 
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Under normal physiological conditions, the level of serum 1,25(OH)2D is 
tightly controlled by the regulation of renal 1α-hydroxylase and 24-
hydroxylase activities. PTH and 1,25(OH)2D itself are considered as the 
most important regulators for the expression of these two enzymes (Omdahl 
et al., 2002). However, increased serum 1,25(OH)2D level along with high 
level of serum PTH has been reported in obese human (Bell et al., 1985, 
Breslau, 1988). On the other hand, an inverse association between serum 
1,25(OH)2D level and BMI was observed in other studies (Konradsen et al., 
2008, Parikh et al., 2004). These evidences suggest altered vitamin D me-
tabolism associated with obesity, however, precise mechanisms have not 
been elucidated.  
Mice have been successfully used as animal models to investigate the 
mechanism of vitamin D. Effects of high dose of vitamin D on calcium and 
vitamin D metabolism (Fleet et al., 2008) and the impact of long-term die-
tary vitamin D deficiency on brain functions (Brouwer-Brolsma et al., 2014) 
have been examined using mice models, both of which were not feasible in 
human studies due to difficulties in tissue collection and lifestyle modifica-
tion on diet. 
In this study, we used high fat diet-induced obese mice model to mini-
mize the differences in lifestyle related factors in obese human such as sun 
exposure and dietary vitamin D intake. We investigated the vitamin D status 
 
- 4 - 
 
and the expression of enzymes involved in vitamin D metabolism in order to 
elucidate the mechanisms responsible for obesity related changes in vitamin 
D status. The specific objectives for this study were to investigate 1) wheth-
er circulating levels of major vitamin D metabolites were influenced by obe-
sity; 2) whether there were any changes in the expression levels of the vita-
min D metabolizing enzymes in liver and kidney due to obesity; 3) whether 
expression levels of these metabolizing enzymes correlated with the serum 
levels of vitamin D metabolites; and 4) whether expressions of vitamin D 
metabolizing enzymes and VDR in adipose tissue were affected by obesity.  
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II.  Literature Review 
1. Obesity and vitamin D  
Obesity has been recognized as a global health problem of great im-
portance and related to many different comorbidities such as dyslipidemia, 
insulin resistance and cardiovascular disease. Interestingly, vitamin D defi-
ciency or inadequacy are also highlighted as the major health problem with 
evidence for links to these chronic diseases. It has long been reported that 
obese subjects frequently have vitamin D deficiency or insufficiency (serum 
25(OH)D concentration below 30 ng/mL), but underlying mechanism be-
tween these two major health problems has not been elucidated yet (Holick, 
2007). 
As a contributor to low 25(OH)D status in obesity, various explanations  
have been suggested, such as: less skin exposure to the sun, impaired ability 
of hepatic synthesis of 25(OH)D by elevated levels of 1,25(OH)2D and PTH, 
and sequestration of vitamin D3 in adipose tissue which has been most often 
invoked (Earthman et al., 2012). Recently, simple volumetric dilutional 
model of vitamin D3 between serum and adipose tissue was suggested as 
another explanation for the low 25(OH)D status in obesity (Drincic et al., 
2012). 
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The relationship between obesity and serum level of the active form of 
vitamin D, 1,25(OH)2D, is not settled yet. The concentration of serum 
1,25(OH)2D is tightly controlled by regulating activities of renal 1α-
hydroxylase and 24-hydroxylase under normal physiological conditions. 
PTH and 1,25(OH)2D itself are considered as the most important regulators 
of these two enzymes’ expression (Omdahl et al., 2002). However, the level 
of serum 1,25(OH)2D has been reported to increase in obese human (Breslau, 
1988), while there are other studies which observed inverse association be-
tween serum 1,25(OH)2D level and obesity. They suggested that serum level 
of 1,25(OH)2D depends on the availability of substrate, 25(OH)D, so low 
level of serum 1,25(OH)2D is also observed in obesity, influenced by de-
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2. Metabolic pathway of vitamin D 
Vitamin D3 is synthesized in the skin from 7-dehydrocholestrol through 
exposure to ultraviolet irradiation and it can also be taken from the diet. Vit-
amin D3 is transported in the blood by vitamin D-binding protein (DBP) to 
the liver where it is hydroxylated by hepatic 25-hydroxylases including 
CYP2R1, CYP27A1, and CYP2J3. The resulting form, 25(OH)D3 is the ma-
jor circulating vitamin D-metabolite which is transported by DBP to the 
kidney. Further hydroxylation of 25(OH)D3 is occurred by 1α-hydroxylase 
(CYP27B1) to produce 1,25(OH)2D3, the biologically active form of vita-
min D (Christakos et al., 2010). Additionally, the 24-hydroxylase (CYP24) 
is clearly known to exist in normal physiology to catabolize 25(OH)D3 and 
degrade 1,25(OH)2D3 to inhibit its biological activity (Jones et al., 2012). 
Meanwhile, it should be noted that another major form of vitamin D, vita-
min D2, undergoes similar metabolic transformations as vitamin D3. Since 
vitamin D3 and vitamin D2 provide various contributions to the overall vit-
amin D status of the body, it is important that both forms are measured total-
ly (Henry, 2011). Therefore, references to vitamin D or its metabolites be-
low will refer to both forms unless otherwise indicated with a specific sub-
script. 
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Figure 1. The metabolic pathway of vitamin D1 (Kitson et al., 2012) 
1CYP2R1, CYP27A1: 25-hydroxylase; CYP24A1: 24-hydroxylase; 
CYP27B1: 1α-hydroxylase; DBP, vitamin D binding protein; RXR, retinoid 
X receptor; VDR, vitamin D receptor; VDRE, vitamin D receptor element.  
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Vitamin D hydroxylases have a P450 notation by nomenclature rules de-
rived for cytochrome P450 superfamily because they were found to contain 
heme-binding and other functional domains typical of cytochrome P450 
hemoprotein enzymes (Henry, 2011). Cytochrome P450-dependent hydrox-
ylases are integral membrane proteins located in either the mitochondria or 
smooth endoplasmic reticulum and require electrons from NADPH to re-
duce molecular O2 to one hydroxyl group and one water molecule. The 
terms P450C25, P450C1, and P450C24 are used to describe these three hy-
droxylases, and they are also named using the term CYP which represents 
cytochrome P450 (Omdahl et al., 2002). 
 
25-hydroxylase 
Since the liver was identified as the major site of 25-hydroxylation of vit-
amin D, there have been several candidates for the 25-hydroxylases. 
CYP2R1 was found to be a highly-conserved and substrate-specific micro-
somal 25-hydroxylase. CYP27A1 was reported to additionally display 25-
hydroxylation of vitamin D and referred to as mitochondrial 25-hydroxylase.  
Recently, other microsomal 25-hydroxylases were also identified such as 
CYP2J2/3, CYP3A4, CYP2D11, and CYP2D25, while only CYP2J2/3 and 
CYP3A4 seem to match the enzymatic properties (Prosser et al., 2004). 
CYP2J3 has been reported to exist only in rat with comparable expression 
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level to that of CYP27A1, and CYP2J2 might be a possible equivalent can-
didate in human but its true physiological meaning in vitamin D 
bioactivation needs further investigation. CYP3A4 is more likely the 24/25-
hydroxylase responsible for the metabolism of vitamin D prodrugs and other 
related therapeutics.  
Among these possible 25-hydroxylases, CYP2R1 is considered as the 
physiological vitamin D 25-hydroxylase at least in human, but is less abun-
dant than CYP27A1 in the liver of mouse and rat (Zhu et al., 2012). Also, 
the mitochondrial vitamin D 25-hydroxylase, CYP27A1, was reported as the 
major 25-hydroxylase in female rat liver, showing 150% higher affinity than 
microsomal 25-hydroxylases (Masumoto et al., 1988).  
 
1α-hydroxylase 
The second step of activation, 1α-hydroxylation of 25(OH)D, mainly oc-
curs in the proximal renal tubule by 1α-hydroxylase (CYP27B1). The 
bioactivation of 25(OH)D to 1,25(OH)2D proceeds at variable rates due to 
regulation of the enzyme’s expression level and the affinity of this enzyme 
differs between species with wide range of Km values. Apart from the major 
substrate, 25(OH)D, 24,25(OH)2D is also the preferred substrate for 
CYP27B1. However, the rate of 1,25(OH)2D synthesis is greater than that of 
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1,24,25(OH)3D synthesis because of the 10-fold higher concentration of 
25(OH)D (Omdahl et al., 2002).  
It is now known that CYP27B1 is also found in extrarenal sites including 
placenta, macrophage, keratinocytes, breast, adipose tissue, and so on. 
Meanwhile, the extrarenal CYP27B1 activity is not regulated by the classi-
cal calcium and phosphate-regulating hormones, but depends specifically on 
the cell’s environment or functions. The extrarenal existence and activity of 
CYP27B1 imply that locally-produced 1,25(OH)2D may increase in various 
intracellular sites by this enzyme and locally trigger nonclassic functions. 
However, further studies are needed to test the specific role of CYP27B1 in 
extrarenal sites (Adams et al., 2012).  
 
24-hydroxylase 
24-hydroxylase (CYP24) is a multicatalytic enzyme that mainly catalyzes 
two substrates, 25(OH)D and 1,25(OH)2D, the latter with a 10-fold higher 
efficiency. Almost all cells express CYP24 in vivo, but the highest activity is 
observed in kidney (Omdahl et al., 2002). CYP24 accelerates the catabolism 
of 1,25(OH)2D to 1,24,25(OH)3D and produces 24,25(OH)2D from 
25(OH)D which is available for 1α-hydroxylation, resulting in decreasing 
the amount of 1,25(OH)2D in target tissues (Christakos et al., 2010). Thus, 
CYP24 plays an important role in the inactivation and clearance of excess 
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vitamin D, controlling 1,25(OH)2D levels. Meanwhile, there is evidence that 
one of the resultants of CYP24, 24,25(OH)2D, has biological properties dis-
tinct from 1,25(OH)2D, but additional evidences are required (Henry, 2011).  
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3. Regulation of the serum 1,25-dihydroxyvitamin D 
Regulation of the vitamin D metabolism mainly focuses on controlling 
serum 1,25(OH)2D level. The serum concentration of 1,25(OH)2D can be 
modulated by a series of negative and positive feedbacks, resulting in 
changes in the expression of the hydroxylases depending on the physiologi-
cal state (Prosser et al., 2004). Low dietary intake of calcium and phosphate 
enhances CYP27B1 activity and the elevated level of PTH stimulates tran-
scription of CYP27B1. The resultant, 1,25(OH)2D itself, can negatively reg-
ulate CYP27B1. The inactivating hydroxylase of vitamin D, CYP24, is re-
ciprocally regulated when compared to CYP27B1 regulation. It is stimulat-
ed by 1,25(OH)2D and inhibited by low serum concentrations of calcium 
and PTH (Christakos et al., 2010).  
Meanwhile, there are some evidences that 25-hydroxylation of vitamin D 
is regulated by circulating 1,25(OH)2D, so 1,25(OH)2D also acts to limit 
production of its precursor, 25(OH)D (Bell et al., 1984). The increased se-
rum 1,25(OH)2D may reduce hepatic synthesis of 25(OH)D by feedback 
inhibition (Bell et al., 1985). 
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4. Vitamin D receptor  
The vitamin D receptor (VDR) is a member of the nuclear receptor su-
perfamily which mediates the actions of 1,25(OH)2D, the hormonal form of 
vitamin D. VDR binds to 1,25(OH)2D with high affinity and specificity, 
then heterodimerises with a retinoid X receptor (RXR) (Ding et al., 2012).  
Once the liganded VDR-RXR heterodimer recognizes vitamin D respon-
sive elements (VDREs) in the DNA sequence of vitamin D-regulated genes, 
a genomic response is generated; the formation of large complexes that can 
facilitate the expression of the targeted gene (coactivators) or inhibit its ex-
pression (cosuppressors). Different tissues have varying levels of these 
coregulators, providing some degree of tissue specificity for vitamin D ac-
tion (Bikle, 2010).  
VDR is clearly present in cells of the intestinal epithelium, renal tubules, 
parathyroid gland cells, skin (keratinocytes), mammary epithelium, pancre-
as (beta islet cells), pituitary gland, skeleton (osteoblasts and chondrocytes), 
immune system (monocytes, macrophages, and T-lymphocytes), and germ 
tissues (Wang et al., 2012). The wide-spread existence of VDR may imply 
the various effects of vitamin D beyond its classical role in calcium home-
ostasis and bone metabolism. Data from clinical studies have provided a 
mechanistic basis for the link between vitamin D deficiency or insufficien-
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cy and lots of disorders, such as inflammatory bowel disease, diabetes, the 
metabolic syndrome, and certain types of cancer. However, the specific 
functions of VDR in many other tissues and cells still remain to be deter-
mined (Ding et al., 2012).  
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5. Nonclassic functions of 1,25-dihydroxyvitamin D in adi-
pose tissue 
1,25(OH)2D has long been recognized to involve in the regulation of cal-
cium and phosphate metabolism mediated by VDR. As 1,25(OH)2D exerts 
its functions by binding VDR, the tissues participating in bone mineral ho-
meostasis such as gut and kidney have been considered as major tissues re-
taining VDR (Bikle, 2009).  
However, VDR has been found in other various tissues, and the 
1,25(OH)2D-VDR interaction in these tissues regulates transcription of a 
number of genes involved in the regulation of many different nonclassic 
functions such as cell proliferation and differentiation, immune function and 
metabolism (Wamberg et al., 2013). 
VDR has also been reported to exist in either human or mouse adipose 
tissue. It implies that adipose tissue can be a target tissue for 1,25(OH)2D 
and have nonclassic functions in it. There are some in vitro studies reporting 
that 1,25(OH)2D may inhibit adipogenesis by suppressing the expression of 
the key adipogenic transcription factors and reducing lipid accumulation in 
adipocytes (Kong et al., 2006).  
On the other hand, recent functional studies of VDR in vivo produced op-
posite results; VDR-null mice were resistant to high fat diet-induced obesity 
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probably owing to increases in energy expenditure and fatty acid β-
oxidation (Wong et al., 2009), and targeted expression of VDR in adipocytes 
induced obesity in mice mainly due to reduced energy expenditure with de-
creased fatty acid β-oxidation and lipolysis in the adipose tissue (Wong et al., 
2011). In addition, another in vitro study suggested that 1,25(OH)2D-VDR 
interaction exerts an inhibitory effect on adipocyte UCP2 expression, modu-
lating adipocyte lipid metabolism and energy homeostasis and local func-
tions (Zemel et al., 2008). Taken together, the current data are inconclusive 
and additional experimental and translational studies are needed to unravel 










Figure 2. The potential functions of 1,25(OH)2D in adipose tissue1 
(Zemel et al., 2008).  
11,25D3 MARRS, 1,25D3 membrane-associated rapid response to steroid; 
11β-HSD, 11β-hydroxysteroid dehydrogenase; Calcitriol, 1,25-
dihydroxyvitamin D (1,25(OH)2D); RXR, retinoid X receptor; UCP, uncou-
pling protein; VDR, vitamin D receptor 
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III. Materials and Methods 
1. Animals and diets 
Four-wk-old male C57BL/6 mice were purchased from Central Labora-
tory Animal Inc. and individually housed under controlled temperature (23 ± 
3°C), humidity (55 ± 10%), and light/dark cycle (12h/12h) conditions in a 
specific pathogen-free room. Mice were fed a control diet during three days 
of acclimation period, then divided into control diet group (control group; 
10% energy as fat, n = 14) or high fat diet group (obese group; 45% energy 
as fat, n = 14). Feeding high fat diet containing 45% kcal as fat for 51 days 
was reported to induce obesity in C57BL/6 mice (Van Heek et al., 1997). 
The composition of experimental diets (Dyets Inc.) is shown in Table 1.  
Diets were fed ad libitum for 18 weeks and dietary intake was assessed 
every other day. Animals were weighed once a week. At the end of the ex-
perimental period, mice were euthanized by CO2 asphyxiation after 12 hours 
of fasting. Blood was obtained by cardiac puncture, serum was isolated by 
centrifugation at 3,000 rpm for 20 minutes after coagulation, and stored at 
−80°C. Liver, kidney, and white adipose tissue (epididymal, subcutaneous, 
perirenal-retroperitoneal, and visceral fat depots) were removed and 
weighed. All tissues were frozen in liquid nitrogen and stored at −80°C un-
til analysis. All animal protocols were approved by Seoul National Universi-
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ty Institutional Animal Care and Use Committee (approval no. SNU-
120709-1).   
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Table 1. Composition of the experimental diets1 
1Resource: Dyets, Inc. 
2Dyetrose (Dyets) is dextrinized cornstarch containing 90-94% 
tetrasaccharides. 
3Thirty-five grams of mineral mix (Dyets, #210099) provides 5.1 g calcium, 
4 g phosphorus, 3.6 g potassium, 1 g sodium, 1.6 g chloride, 0.5 g magnesi-
um, 0.3 g sulfur, 59 mg manganese, 46 mg iron, 25 mg zinc, 5 mg copper, 
0.2 mg selenium, 0.2 mg iodine, and 4.2 g sucrose.  
4Ten grams of vitamin mix (Dyets, #300050) provides 4,000 IU vitamin A, 
1,000 IU vitamin D3, 50 IU vitamin E, 30 mg niacin, 16 mg pantothenic ac-
id, 7 mg vitamin B6, 6 mg vitamin B1, 6 mg vitamin B2, 2 mg folic acid, 0.8 
mg menadione, 0.2 mg biotin, 10 μg vitamin B12 and 9.8 g sucrose.  
Item Control diet High-fat diet 
 gram kcal gram kcal 
Casein 200 716 200 716 
L-Cystine 3 12 3 12 
Sucrose 350 1400 172.8 691 
Cornstarch 315 1134 72.8 262 
Dyetrose2 35 133 100 380 
Soybean Oil 45 405 45 405 
Lard 0 0 157.5 1418 
t-Butylhydroquinone 0.009 0 0.009 0 
Cellulose 50 0 50 0 
Mineral Mix3 35 16.5 35 16.5 
Vitamin Mix4 10 39.2 10 39.2 
Choline Bitartrate 2 0 2 0 
Total  1045.009 3855.7 848.109 3939.7 
kcal/gram diet 3.69 4.65 
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2. Quantification of serum 25-hydroxyvitamin D 
Serum 25(OH)D was measured using a commercial 25-Hydroxyvitamin 
D 125I RIA kit from DiaSorin (DiaSorin Inc.) as directed by the manufactur-
ers’ product inserts. The 25(OH)D analysis largely consists of a two-step 
procedure. The first procedure is a rapid extraction of 25(OH)D and other 
hydroxylated metabolites from serum with acetonitrile and the following 
procedure is assaying the extracted sample using an equilibrium radioim-
munoassay (RIA) method based on an antibody with specificity to 25(OH)D.  
In the extraction procedure, 500 μL of acetonitirile was added to each 10 
x 75 mm borosilicate glass tube for each calibrator, control and serum sam-
ple. Six 25(OH)D calibrators at concentrations ranging from 0-100 ng/mL 
and two 25(OH)D controls (low-normal and high-normal range) were pro-
vided from the kit. Fifty μL of calibrators, controls and serum samples were 
added slowly into the acetonitrile. After vortexing for 10 seconds, all tubes 
were centrifuged at 1,200 ×g for 10 minutes at 25°C. Twenty-five μL ali-
quots from the supernatant were transferred in duplicate to each fresh tube. 
The whole RIA procedure was performed in the RIA laboratory. In addi-
tion to tubes from extraction procedure, Total counts (Tcts) and Non-specific 
binding (NSB) tubes were also prepared. Whereas nothing was added to 
Tcts tubes, 25 μL aliquots from the supernatant of extracted Calibrator 0 (0 
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ng/ml) were transferred in duplicate to each NSB tube. Fifty μL of 125I 
25(OH)D tracer and 1 mL of 25(OH)D antiserum were added to each tube 
of extracted calibrators, controls and serum samples, but 1 mL of NSB buff-
er was added instead of 25(OH)D antiserum to each Tcts and NSB tube. Af-
ter vortexing without allowing the contents to foam, all tubes were incubat-
ed for 90 minutes at room temperature. Five hundred μL of Donkey Anti-
Goat precipitating complex was added to all tubes except for Tcts tubes. All 
tubes were vortexed gently to mix well and centrifuged at 1,800 ×g for 20 
minutes at 25°C. Supernatants were decanted to leave pellets only, then each 
tube was counted in the Gamma scintillation counter (2480 WIZARD2 ® 
gamma counter, PerkinElmer) for 1 minute.  
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3. Quantification of serum 1,25-dihydroxyvitamin D  
Serum 1,25(OH)2D was also analyzed via RIA using a commercial 1,25-
Dihydroxyvitamin D 125I RIA kit from Immunodiagnostic Systems (IDS 
Ltd.). The assay system consists of two main steps; the first step is a purifi-
cation of 1,25(OH)2D in samples and controls by immunoextraction and the 
following step is quantification of 1,25(OH)2D by 125I RIA.   
In the immunoextraction step, two immunocapsules containing monoclo-
nal antibody to 1,25(OH)2D were prepared for each delipidated control and 
serum sample. A hundred μL of controls and serum samples was added to 
immunocapsules and all immunocapsules were rotated end-over-end at 10 
revolution per minute for 3 hours at room temperature. After removing 
screw caps and bottom stoppers, all immunocapsules were placed in each 
labelled plastic tube and centrifuged at 700 ×g for 60 seconds at 4°C. Five 
hundred μL of diluted Wash Solution was added to each immunocapsule and 
all tubes with immunocapsules were centrifuged at 700 ×g for 60 seconds at 
4°C. After repeating this washing step again, the labelled borosilicate glass 
tubes, one for each immunocapsule, were prepared and all immunocapsules 
were transferred to each glass tube. A hundred and fifty μL of Elution Rea-
gent, which elutes 1,25(OH)2D from immunocapsules, was added to each 
immunocapsule and incubated for 2 minutes. All tubes with 
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immunocapsules were centrifuged at 700 ×g for 60 seconds at 4°C and this 
elution step was repeated two times. Immunocapsules were discarded and 
the elutes in the glass tubes were evaporated under a gentle flow of nitrogen 
for 20-30 minutes at 30°C to leave white pellet only in the tubes. A hundred 
μL of Assay Buffer was added to each tube and then the immunopurified 
samples and controls were ready for the RIA step. 
The whole RIA procedure was performed in the RIA laboratory. In addi-
tion to extract tubes from immunoextraction step, appropriately labelled bo-
rosilicate glass tubes were also prepared two for each calibrator, Non-
specific binding (NSB), and Total Counts (Tcts). A hundred μL of each cali-
brator was added to each labelled tube and 300 μL of Assay Buffer was add-
ed to NSB tubes. Except NSB tubes, 200 μL of Primary Antibody (Ab) was 
added to all tubes. Then all tubes were vortexed gently without foaming and 
incubated for 16 hours at 4°C. Two hundred μL of 125I 1,25(OH)2D Assay 
Buffer was added to all tubes including NSB and Tcts tubes. After vortexing 
without allowing the contents to foam, all tubes were incubated for an hour 
at room temperature. Four mL of diluted Wash Solution was added to all 
tubes except Tcts tubes. All tubes were centrifuged at 2,000 ×g for 20 
minutes at 4°C. Supernatants were decanted to leave pellets only, then each 
tube was counted in the Gamma scintillation counter (2480 WIZARD2 ® 
gamma counter, PerkinElmer) for 1 minute.   
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4. Quantification of serum parathyroid hormone  
Serum PTH was quantified by two-site enzyme-linked immunosorbent 
assay (ELISA) with the commercial mouse intact parathyroid hormone 
(PTH 1-84) ELISA kit (Immutopics Inc.). 
The sufficient number of streptavidin coated eight well strips were pre-
pared in a 96-wells plate holder to run PTH standards, controls and un-
known samples, then 20 μL of standards, controls, and samples was pipetted 
in duplicate into the designated well. Following that, 50 μL of Working An-
tibody Solution consisting of equal volumes of mouse PTH 1-84 
Biotinylated Antibody and mouse PTH 1-84 HRP Conjugated Antibody was 
added into each well. The plate was covered with a plate sealer and an alu-
minum foil again to block the light, then incubated for three hours at 25°C 
on a horizontal rotator set at 220 RPM. After uncovering the aluminum foil 
and the plate sealer, each well was washed by pipetting 350 μL of Washing 
Solution and completely removing the contents five times in a row. A hun-
dred μL of ELISA HRP Substrate was pipetted into each of the wells, then 
the plate was incubated for 30 minutes at 25°C on a horizontal rotator set at 
220 RPM, covered again with a plate sealer and an aluminum foil.  
Before the addition of the ELISA Stop Solution, the plate sealer and alu-
minum foil were removed and the absorbance at 620 nm was read in a 
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microplate reader against the 0 pg/mL standard wells as a blank. After im-
mediately adding 100 μL of ELISA Stop Solution into each well, the plate 
was mixed for 1 minute on a horizontal rotator. This time, the absorbance at 
450 nm was read in the microplate reader against a reagent blank of 100 μL 
of HRP Substrate and 100 μL of ELISA Stop Solution. Two standard curves 
based on the two absorbance readings at 620 nm and 450 nm are required 
for the calculation of the sample results. The first reading taken at 620 nm is 
used for constructing the secondary standard curve which is applied only for 
sample results that fall between the value of the fifth and sixth standards. 
The second reading taken at 450 nm is for the primary standard curve which 
utilizes the absorbance values obtained with the first five standards. All 
sample results were within the analytical range of the primary standard 
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5. Quantification of serum calcium  
Serum calcium (Ca) concentration was determined by ortho-
cresolphthalein complexone (OCPC) method using AceChem Ca Kit (YD 
Diagnostics). This assay utilizes the reaction between calcium and ortho-
cresolphthalein which forms a complex with a purple color that absorbs be-
tween 560 and 590 nm. The intensity of the color is proportional to the con-
centration of calcium in the sample.  
To prepare the working reagent, equal volumes of Reagent A (assay buffer) 
and Reagent B (chromogenic reagent) were combined and vortexed lightly. 
Five μL of diluted standards and samples was pipetted in duplicate into 
wells of a clear bottom 96-well plate, then 250 μL of working reagent was 
added to each well and tapped lightly to mix. The plate was incubated for 5 
minutes at 37°C in a water bath and the optical density was measured at 546 
nm in the microplate reader. The concentration of Ca in the sample was cal-
culated using the equation obtained from the standard curve.   
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6. RNA extraction and cDNA synthesis  
After extracting total RNA and synthesizing cDNA from liver, kidney, 
and visceral adipose tissue (VAT), mRNA expression of vitamin D hydrox-
ylase and VDR were analyzed by real-time PCR. Fifty to seventy mg of 
each tissue was homogenized in 1 mL of TRIzol reagent (Invitrogen) and 
incubated for five minutes at room temperature. Following the addition of 
200 μL of chloroform, all samples were vortexed and incubated for 3 
minutes, then centrifuged at 12,000 ×g for 15 minutes at 4°C. The separated 
supernatants were transferred to fresh tubes and 500 μL of isopropanol was 
pipetted to each tube. After 10 minutes of incubation at room temperature, 
all tubes were centrifuged at 12,000 ×g for 10 minutes at 4°C. The aqueous 
phase was removed by drying at room temperature and only RNA pellets 
were left in the tube. To wash the RNA pellet, 1 mL of 75% ethanol was 
added and vortexed, then centrifuged for 2 minutes at 4°C. Supernatants 
were decanted again and the left RNA pellets were dried in the air. The ex-
tracted total RNA solution was obtained after adding 20 μL of 0.2% 
diethylpyrocarbonate (DEPC)-treated water to dissolve the RNA pellet in 
each tube. The qualities of the RNA samples were examined by agarose gel 
electrophoresis using Gel Doc XR system (Bio-Rad Laboratories Inc.). The 
 
- 30 - 
 
concentration of RNA solutions was quantified by measuring absorbance at 
260 nm and 280 nm using a spectrophotometer (DU530, BECKMAN).  
Two μg portion of total RNA was reverse-transcribed into cDNA with 
PrimeScriptTMⅠ1st strand cDNA synthesis kit (Takara Bio Inc.). The 
cDNA synthesis reaction was performed at 42°C for 50 minutes and stopped 
by denaturing at 95°C for 5 minutes using Applied Biosystems Thermal Cy-
cler 2720 (Life technologies co.).  
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7. Real-time PCR for mRNA analysis 
mRNA levels of 25-hydroxylases (CYP2R1, CYP27A1, CYP2J3) in liver 
and adipose tissue, 24-hydroxylase (CYP24) and 1α-hydroxylase 
(CYP27B1) in kidney, and VDR in adipose tissue were determined by real-
time PCR. A total of 20 μL PCR reaction mixture containing the specific 
primers, reverse-transcribed cDNA, ROX reference dye, SYBR Premix Ex 
Taq (Takara Bio Inc.) and autoclaved distilled water was prepared for each 
sample. The sequences of specific primers are shown in Table 2.  
All PCR reactions were performed using StepOne Real-time PCR sys-
tem (Applied Biosystems) under the following steps and conditions; initia-
tion step at 95°C for 30 seconds, denaturation step at 95°C for 5 seconds, 
annealing and extension step at 60°C for 30 seconds up to 40 cycles, and 
melting curve analysis at 95°C for 15 seconds, 60°C for 1 minute, and 95°C 
for 15 seconds. 
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Table 2. Primer sequences used in real-time quantitative PCR 
Gene Function Forward primer (5’ – 3’) Reverse primer (5’ – 3’) 
Cyp2r1 25-hydroxylation TGGTGAGGTAAATGAGGCTTTC TGCCAGTGCTCCAGTCTTC 
Cyp27a1 25-hydroxylation CCAAGGCAAGGTGGTAGAGA CTTCATCGCACAAGGAGAGC 
Cyp2j3 25-hydroxylation ACCTCCTTTGCTCCTTCCAT CAGCCACACCTATCCCTTCA 
Cyp27b1 1-hydroxylation GACGATGTTGGCTGTCTTCC ATCTCTTCCCTTCGGCTTTG 
Cyp24 24-hydroxylation TCCCTGAGTAATGGGCTTTG CACGGTAGGCTGCTGAGATT 
Vdr vitamin D receptor ATGTCCAGTGAGGGGGTGTA TGTCTGAGGAGCAACAGCAC 
Gapdh house-keeping gene GGAGAAACCTGCCAAGTA AAGAGTGGGAGTTGCTGTTG 
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8. Total protein extraction and western blot 
Total protein was extracted from liver tissue and the expression of specif-
ic proteins was determined by western blot analysis. To extract total protein, 
500 mg tissue was added to 500 μL of radioimmunoprecipitation assay 
(RIPA) buffer and homogenized on ice. The composition of RIPA is as fol-
lows; 50 μM Tris-Cl (pH 7.4), 1% NP-40, 0.25% Na-deoxycholate, 150 mM 
NaCl, 1mM EDTA, 1 mM PMSF, 1 mM Na3VO4, 1 mM sodium pyrophos-
phate, 1 mM β-glycerophosphate, 10% glycerol, protease inhibitor cocktail 
1 tablet/10 ml (Roche). The homogenates were incubated on ice for 30 
minutes and centrifuged at 12,000 rpm for 20 minutes at 4°C. Supernatants 
were transferred to fresh tubes and concentrations of extracted total protein 
were determined by Bradford assay. BSA standard was diluted into 0.01, 
0.02, 0.05, 0.1, 0.2, 0.5 and 1.0 mg/mL concentrations and 50X, 100X, and 
200X diluted protein extracts were prepared. Ten μL of each standard and 
protein extract solution were pipetted into the appropriate well on 96-well 
plate, then 200 μL of 5X diluted Bradford assay reagent (Bio-Rad Laborato-
ries Inc.) was added to each well. After incubating for 5 minutes at room 
temperature, the absorbance at 595 nm was measured. The most appropriate 
dilution concentration of protein extract was determined by using the stand-
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ard curve, and the concentration of protein was calculated. Protein extracts 
were stored at −80°C before analysis.  
Protein levels of 25-hydroxylase (CYP27A1) in liver were evaluated by 
western blot analysis. The 95:5 volume ratio of Laemmli sample buffer 
(Bio-Rad Laboratories Inc.)-β-mercaptoethanol solution and distilled water 
were added to protein extracts from liver and kidney to make appropriate 
concentration for each specific protein. Forty µg of protein samples were 
separated on a precast 10% SDS-PAGE gel and transferred to PVDF mem-
brane (Bio-Rad Laboratories Inc.). Membranes were blocked overnight at 
4°C in 5% skim milk solution (Tris buffer-saline solution with 0.1% Tween 
20 and 5% skim milk), then incubated overnight at 4°C in 5% skim milk 
solution with goat anti-CYP27A1 (1:200 dilution, Santa Cruz Biotechnolo-
gy Inc.) or with mouse anti-β-actin (1:10,000 dilution, Sigma-Aldrich Co.), 
and washed 4 times with TBST solution (Tris buffer-saline solution with 0.1% 
Tween 20). The blots were next applied in 5% skim milk solution with anti-
goat IgG-HRP (1:8,500 dilution, Abcam plc.) or with anti-mouse IgG-HRP 
(1:20,000 dilution, Invitrogen) for 1 hour, then washed 4 times with TBST 
solution. Finally, the membranes were incubated in ECL solution (Animal 
Genetics Inc.) for 1 minute in the dark room and expressions of specific pro-
teins were detected on X-ray film. Band density was analyzed using the 
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9.  Statistical analysis 
Statistical analysis was performed using SPSS statistical software (ver-
sion 21.0; SPSS Inc.). To compare differences between control and obese 
groups, Mann-Whitney U-test or Student’s t-test was used based on the re-
sults of Kolmogorov-Smirnov test for normal distribution. Correlations be-
tween two variables were assessed using the Pearson correlation test. P-
value less than 0.05 was considered statistically significant.  
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IV. Results 
1. Body weight, weight gain, white adipose tissue weight, and 
dietary intake 
After 18-wk of feeding period, mice fed the high fat diet had significantly 
higher body weight (58% higher, P < 0.001) and white adipose tissue weight 
(90% higher, P < 0.001) compared with the mice fed the control diet (Fig-
ure 3). Van Heek et al. (Van Heek et al., 1997) observed high fat diet (45% 
kcal fat diet) group became 25% heavier than control diet (10% kcal fat diet) 
group in C57BL/6 mice, and reported that obesity was induced in high fat 
diet group by feeding high fat diet contained 45% kcal as fat over a period 
of 51 days. Thus, we could speculate that obesity was successfully induced 
in high fat diet fed mice in this study and these mice could be considered as 
obese group. 
Although daily food intake was 12% lower in the obese group, daily en-
ergy intake was 9% higher because of the higher percent of fat in the high 
fat diet. High fat diet contained 23% higher vitamin D and Ca than control 
diet (960 IU vitamin D and 5.0 g Ca per kg diet in control vs. 1180 IU vita-
min D and 6.1 g Ca per kg diet in high fat), but daily intake of vitamin D 
and Ca were 6% higher in the obese group due to lower daily food intake in 
obese group (Table 3).  
 















Figure 3. Body weight change of the mice fed control or high fat diets 
Mice were fed control (10% energy as fat) or high fat (45% energy as fat) 
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Table 3. Body weight, weight gain, white adipose tissue weight, and dietary intake of the mice fed control or high fat diets1 
 
1 Data are presented as means ± SEM, n = 14 for each group.  
2 Student’s t-test was performed to determine the significant effect of obesity. A P-value of < 0.05 was considered statistically signif-
icant.
 Control Obese P-value2 
Body weight at 0 week, g   16.96 ± 0.31 16.77 ± 0.25 0.643 
Body weight at 18 week, g   37.53 ± 0.76 49.24 ± 0.31 < 0.001 
Body weight gain, g   20.57 ± 0.94 32.46 ± 0.28 < 0.001 
White adipose tissue weight, g   3.94 ± 0.17 7.47 ± 0.16 < 0.001 
Daily food intake, g/d   3.44 ± 0.04 3.02 ± 0.04 < 0.001 
Daily vitamin D intake, IU/d 3.29 ± 0.04 3.56 ± 0.05 < 0.001 
Daily calcium intake, mg/d 17.48 ± 0.22 18.51 ± 0.25 < 0.001 
Daily energy intake, kcal/d 12.73 ± 0.16 13.89 ± 0.18 < 0.001 
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2. Serum concentrations of vitamin D metabolites and calcium 
Serum concentrations of 25(OH)D and 1,25(OH)2D were measured in or-
der to investigate whether circulating levels of major vitamin D metabolites 
were influenced by obesity. There was no difference in serum 25(OH)D 
concentration between control group (27.63 ± 0.73 ng/mL) and obese group 
(30.30 ± 1.44 ng/mL) (Figure 4A), while serum 1,25(OH)2D concentration 
was significantly higher (P < 0.05) in obese group (222.00 ± 40.56 pg/mL) 
than control group (107.12 ± 14.37 pg/mL) (Figure 4B). Serum Ca concen-
trations were not significantly different between control group (12.58 ± 0.31 
mg/dL) and obese group (13.38 ± 0.57 mg/dL) (Figure 4C). 
 
 











Figure 4. Serum concentrations of 25(OH)D (A), 1,25(OH)2D (B), and calcium (C) 
Serum vitamin D metabolites’ levels were measured by radioimmunoassay and serum calcium levels were measured by ortho-
cresolphthalein complexone method. Values are expressed as means ± SEM, n = 10 for serum 25(OH)D, n = 6 for serum 
1,25(OH)2D and n = 9 for serum calcium for each group. *Significantly different compared with the control by Student’s t-test, P < 
0.05.  
A                          B                          C                                      
 
 
- 42 - 
 
3. Serum concentration of parathyroid hormone  
To examine whether secondary hyperparathyroidism, which could influ-
ence the regulation of renal 1α-hydroxylase, occurred in obesity, serum con-
centration of PTH was analyzed. Obese group had significantly higher (P < 
0.05) serum PTH concentration than control group (161.84 ± 22.12 pg/mL 
in obese vs. 100.66 ± 13.28 pg/mL in control) (Figure 5), and serum con-











Figure 5. Serum concentration of PTH 
Serum PTH levels were measured by two-site enzyme-linked 
immunosorbent assay. Values are expressed as means ± SEM, n = 6 for each 
group. *Significantly different compared with the control by Student’s t-test, 
P < 0.05. 
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4. Expression of hepatic 25-hydroxylases 
To evaluate whether the major contributors of the 25(OH)D synthesis 
were affected by obesity, expression of 25-hydroxylases in liver was deter-
mined. The mRNA levels of three hepatic 25-hydroxylases, Cyp2r1, 
Cyp27a1 and Cyp2j3, were significantly lower (31% lower, P < 0.001; 30% 
lower, P < 0.05; 48% lower, P < 0.05, respectively) in obese group than 
control group (Figure 6A).  
In order to find out whether differences in 25-hydroxylase mRNA level 
resulted in changes at the protein level, CYP27A1 protein expression was 
measured. However, the significant difference in the expression of Cyp27a1 
at mRNA level between control and obese groups was not sustained at the 
protein level as there was no significant difference in CYP27A1 protein lev-
els (Figure 6B). 
  
 






















Figure 6. Hepatic expression of vitamin D 25-hydroxylases. mRNA lev-
els of Cyp2r1, Cyp27a1, and Cyp2j3 (A) and protein level of CYP27A1 (B)  
The mRNA levels were measured by quantitative RT-PCR. All levels were 
normalized to the levels of house-keeping gene, Gapdh, and expressed as 
relative values compared with the control (A). The protein expression level 
was analyzed by western blot and the quantification of the blot was done by 
densitometric analysis. CYP27A1 protein expression level was normalized 
to the protein expression level of β-actin and presented as relative values 
compared with the control (B). Values are expressed as means ± SEM, n = 
10 for each group. *Significantly different compared with the control by 
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5. Expression of renal 1α-hydroxylase and 24-hydroxylase 
Serum 1,25(OH)2D concentration is regulated by the balance between ac-
tivation of 25(OH)D by renal 1α-hydroxylase and inactivation of 
1,25(OH)2D by renal 24-hydroxylase. As significantly higher serum 
1,25(OH)2D concentration was observed in obese group, we examined 
whether there were any changes in the expression of these two renal hy-
droxylases due to obesity. Renal Cyp27b1 mRNA level was upregulated 
(517% higher, P < 0.01) and Cyp24 mRNA level was downregulated (48% 
lower, P < 0.05) in obese group compared with control group (Figure 7). 
Cyp27b1 mRNA level correlated positively with serum 1,25(OH)2D concen-
tration (r = 0.74, P < 0.01) (Figure 8A), and Cyp24 mRNA level showed 
negative correlation with serum 1,25(OH)2D concentration (r = −0.68, P < 
0.01) (Figure 8B).  
  
 















Figure 7. Renal expression of vitamin D 1α-hydroxylase and 24-
hydroxylase 
The mRNA levels were measured by quantitative RT-PCR. All levels were 
normalized to the levels of house-keeping gene, Gapdh, and expressed as 
relative values compared with the control. Values are expressed as means ± 
SEM, n = 10 for each group. *Significantly different compared with the 
control either in renal 1α-hydroxylase expression by Mann-Whitney U-test 











Figure 8. Relationship between serum 1,25(OH)2D and renal Cyp27b1 
mRNA level (A) or renal Cyp24 mRNA level (B) 
Pearson correlation test was performed to determine the association between 
serum 1,25(OH)2D and renal mRNA expressions of Cyp27b1 (A) or Cyp24 
(B), and the coefficient of determination of each correlation is shown.  
  
A                              B                             
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6. Expression of 25-hydroxylases and vitamin D receptor in 
visceral adipose tissue 
To evaluate the existence of local vitamin D metabolism in adipose tissue, 
mRNA levels of vitamin D hydroxylases in VAT were measured. Obese 
group had significantly higher mRNA levels of 25-hydroxylases, Cyp27a1 
and Cyp2j3 (68% higher, P < 0.05; 126% higher, P < 0.01 respectively), 
compared with control group (Figure 9A). However, 1α-hydroxylase 
(Cyp27b1) and 24-hydroxylase (Cyp24) were not detectable in VAT from 
mice in this study.  
In order to determine whether expression of VDR in adipose tissue is in-
fluenced by obesity, we measured Vdr mRNA levels in VAT, and found that 
obese group had significantly higher Vdr mRNA level than control group (P 
< 0.01) (Figure 9B).  
  
 







Figure 9. Expression of vitamin D 25-hydroxylases (A) and Vdr (B) in 
visceral adipose tissue 
The mRNA levels were measured by quantitative RT-PCR. All levels were 
normalized to the levels of house-keeping gene, Gapdh, and expressed as 
relative values compared with the control. Values are expressed as means ± 
SEM, n = 5-6 for each group. *Significantly different compared with the 
control by Student’s t-test, P < 0.05. 
 
  
A                                      B                             
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V.  Discussion 
In this study, we investigated the impact of obesity on vitamin D status 
and the possible underlying mechanism of altered vitamin D metabolism by 
examining the expressions of genes and protein related to vitamin D metab-
olism in high fat diet-induced obese mice. An abnormal regulation of serum 
1,25(OH)2D was observed in obese mice, which seemed to be associated 
with increased PTH level and explained by alterations in the expression of 
major vitamin D metabolizing enzymes, 1α-hydroxylase and 24-
hydroxylase, in the kidney. 
There was no difference in circulating 25(OH)D concentration between 
control and obese groups in this study. In human, however, obesity has often 
been associated with low status of vitamin D (Earthman et al., 2012). 
Among several possible explanations for vitamin D deficiency in obese 
people, inadequate sun exposure and suboptimal dietary vitamin D intake 
were often suggested (Earthman et al., 2012). The vitamin D content of two 
experimental diets in this study were 960 IU/kg in control diet and 1180 
IU/kg in high fat diet, which were close to NRC requirement for vitamin D 
in rodents’ diets, 1000 IU/kg (Subcommittee on Laboratory Animal 
Nutrition, 1995). Although high fat diet contained 23% more vitamin D per 
weight diet than the control diet, the actual intake of vitamin D was 6% 
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more in the obese group because of less food intake in high fat diet-fed mice. 
In a study which observed the significant difference in serum concentrations 
of 25(OH)D and 1,25(OH)D by dietary vitamin D supplementation in rats, 
257% more vitamin D was fed in the vitamin D-supplemented diet group 
than the conventional diet group (Vieth et al., 2000). Therefore, 6% differ-
ence in dietary vitamin D intake between two groups in this study is not 
likely to have significant influence on serum vitamin D concentrations.  
Although serum 25(OH)D concentration was not significantly different in 
obese group compared with control group, mRNA levels of hepatic 25-
hydroxylases, Cyp2r1, Cyp27a1, and Cyp2j3, were significantly lower in 
obese group. Protein expression of 25-hydroxylase, CYP27A1, was similar 
between control and obese groups despite a difference in mRNA levels, 
which might explain no difference in serum 25(OH)D level between two 
groups. In a study which investigated the expression of enzymes involved in 
vitamin D metabolism in endometriosis and ovarian cancer, the observed 
difference in the Cyp27a1 mRNA level in ovaries between control group 
and ovarian cancer group was not maintained at the protein level (Agic et al., 
2007). There is a possibility that protein expression of other two 25-
hydroxylases, CYP2R1 and CYP2J3, might be different. However, mito-
chondrial vitamin D 25-hydroxylase was shown to have 1.5 fold higher ac-
tivity than microsomal vitamin D 25-hydroxylase in rat liver (Masumoto et 
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al., 1988), and we observed more abundant expression of mitochondrial 25-
hydroxylase, Cyp27a1, than two microsomal 25-hydroxylases, Cyp2r1 and 
Cyp2j3, in the liver. Therefore, even if there is a differential protein expres-
sion of other two 25-hydroxylases, it may not have a significant influence 
on the entire hepatic 25-hydroxylation of vitamin D. 
In adipose tissue, expressions of 25-hydroxylases, Cyp27a1 and Cyp2j3, 
were more pronounced in obese mice. These findings suggest a possibility 
of promoted 25-hydroxylation in adipose tissue from obese mice, resulting 
in higher local production of 25(OH)D in adipose tissue. According to the 
recently proposed volumetric dilutional model of vitamin D3 between serum 
and adipose tissue, the synthesized or ingested vitamin D3 would be distrib-
uted to the serum and adipose tissue in a simple bidirectional and diffusional 
equilibrium (Drincic et al., 2012). Further, it was suggested that similar 
mechanism with regard to 25(OH)D might exist between serum and adipose 
compartments (Piccolo et al., 2013). In obese mice in this study, more 
25(OH)D could be synthesized from adipose tissue due to higher 25-
hydroxylase expression and more adiposity with obesity, which might have 
an influence on the circulating level of 25(OH)D and could explain similar 
levels of serum 25(OH)D despite a lower expression of hepatic 25-
hydroxylases observed in obese mice.  
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In this study, 1,25(OH)2D, an important vitamin D metabolite in circula-
tion and whose level is tightly regulated in normal physiological condition, 
was significantly higher in obese group. Serum concentration of PTH was 
measured because PTH is the principal regulator of the renal 1,25(OH)2D 
synthesis by stimulating 1α-hydroxylase. Higher concentration of PTH was 
observed in the obese mice, although there was no difference in serum Ca 
concentration between two groups. In addition, serum PTH level correlated 
positively with the body weight in this study. Bell et al. (Bell et al., 1985) 
observed higher serum PTH and 1,25(OH)2D, and lower serum 25(OH)D in 
obese subjects compared with the nonobese subjects despite a similar serum 
calcium and phosphorus levels when they were maintained for same dietary 
calcium and phosphorus intake for 2 days. They suggested altered vitamin D 
endocrine system due to secondary hyperparathyroidism, leading to in-
creased renal production of 1,25(OH)2D, however, direct evidence or mech-
anism for increased 1,25(OH)2D was not provided. 
Mechanism of elevated 1,25(OH)2D concentration with obesity was fur-
ther investigated by looking at the mRNA expressions of renal Cyp27b1 and 
Cyp24. Renal Cyp27b1 mRNA expression was upregulated and Cyp24 
mRNA expression was downregulated in the obese mice, which is the first 
observation to our knowledge. Furthermore, serum 1,25(OH)2D level 
showed positive correlation with renal Cyp27b1 mRNA expression and neg-
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ative correlation with renal Cyp24 mRNA expression. When varied amount 
of dietary Ca intake was used to modulate 1,25(OH)2D levels in rats, serum 
1,25(OH)2D levels had positive relationship with renal Cyp27b1 mRNA 
levels and negative relationship with renal Cyp24 mRNA levels (Anderson 
et al., 2004). This result clearly showed that renal mRNA levels of Cyp27b1 
and Cyp24 are closely associated with serum 1,25(OH)2D level. Thus, high-
er serum 1,25(OH)2D level in obese mice in this study could be attributed to 
the alterations in the expression of renal 1α-hydroxylase and 24-hydroxylase. 
In the present study, difference in dietary Ca intake between control and 
obese groups was small and circulating Ca level was similar between two 
groups, but significant differences in renal mRNA expression of Cyp27b1 
and Cyp24 between two groups were observed. PTH was reported to stimu-
late renal Cyp27b1 expression (Brenza et al., 2000) and attenuate renal 
Cyp24 expression (Zierold et al., 2000). The treatment of PTH in AOK-B50 
cells, a porcine proximal tubule cell line with stably transfected opossum 
PTH receptor, and in HKC-8 cells, an SV40 transformed human kidney cell 
line, rapidly increased Cyp27b1 transcript level (Brenza et al., 2000). Cyp24 
mRNA expression and activity were repressed by PTH in AOK-B50 cells 
(Zierold et al., 2000). The increases in PTH due to obesity in this study 
might be responsible for the higher Cyp27b1 and lower Cyp24 expression, 
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resulting in stimulation of renal 1,25(OH)2D production and subsequent in-
crease in serum 1,25(OH)2D.  
Available evidence by in vivo study in normal human subjects indicated 
that 1,25(OH)2D inhibited the hepatic production of 25(OH)D (Bell et al., 
1984), and it was reported that the reduction in serum 25(OH)D in obese 
human might be attributed to this feedback regulation by elevated 
1,25(OH)2D (Bell et al., 1985). However, these previous studies could not 
provide the direct mechanism for the feedback regulation of 25(OH)D pro-
duction. In the present study, we observed that mRNA expressions of all 
three hepatic 25-hydroxylases were lower in obese mice and expression of 
each hydroxylase showed negative correlation with serum 1,25(OH)2D, es-
pecially Cyp2r1 mRNA expression showed significantly negative correla-
tion (r = −0.67, P < 0.05) with serum 1,25(OH)2D. This might indicate a 
feedback inhibition of hepatic 25-hydroxylation at mRNA level by the in-
creased level of serum 1,25(OH)2D with obesity.  
The biologically active form of vitamin D, 1,25(OH)2D, performs its 
functions by interacting with nuclear VDR. We observed that Vdr mRNA 
was expressed in VAT of both mice groups, and obese group had higher Vdr 
expression compared with control group. It was suggested that 1,25(OH)2D 
exerted nonclassic actions mediated by nVDR on adipocyte such as inhibit-
ing UCP2 expression and thereby suppressing energy expenditure. The sup-
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pression of 1,25(OH)2D by increasing dietary calcium not only increased 
UCP2 expression but also stimulated lipolysis and inhibited lipogenesis, re-
sulting in reduced adiposity (Shi et al., 2001, Zemel et al., 2000). As both 
serum 1,25(OH)2D level and Vdr mRNA expression in adipose tissue were 
higher in obese mice, there is a possibility that increased access of 
1,25(OH)2D to adipose tissue and elevated interaction with nVDR would 
further stimulate adiposity.  
In conclusion, high fat diet-induced obesity influenced the expression of 
vitamin D metabolizing enzymes, which could provide possible mechanisms 
of altered vitamin D metabolism in obesity. Higher concentration of serum 
PTH in obese mice might have contributed to the abnormal regulation of 
serum 1,25(OH)2D concentration by stimulating 1α-hydroxylase expression 
and attenuating 24-hydroxylase expression in kidney. The increase in serum 
1,25(OH)2D could have potentially inhibited hepatic synthesis of 25(OH)D 
at mRNA level. Further, higher expression of 25-hydroxylases and VDR in 
adipose tissue might suggest the possibility of enhanced local 25(OH)D 
production and nonclassic functions by the interaction between 1,25(OH)2D 
and VDR in adipose tissue. 
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VI. Summary 
In this study, we investigated the vitamin D status and the expression of 
enzymes involved in vitamin D metabolism using high fat diet-induced 
obese mice in order to find out the possible underlying mechanism respon-
sible for obesity related changes in vitamin D status. Mice were fed control 
diet containing 10% energy fat (control group) or high fat diet with 45% en-
ergy fat (obese group) for 18 weeks, then serum concentrations of vitamin D 
metabolites, calcium, PTH and the expression of enzymes involved in vita-
min D metabolism were analyzed. The results obtained in the present study 
can be summarized as follows: 
1) Obese group had significantly higher body weight and white adipose 
tissue weight than control group. Daily intake of vitamin D and Ca were 
6% higher in the obese group. 
2) No difference was observed in serum 25(OH)D concentration between 
control group and obese group. But, obese group had significantly lower 
mRNA levels of three hepatic 25-hydroxylases, Cyp2r1, Cyp27a1 and 
Cyp2j3 compared with the control group. There was no significant dif-
ference in CYP27A1 protein levels between two groups. 
3) While serum Ca concentration was not significantly different between 
two groups, serum concentrations of 1,25(OH)2D and PTH were signifi-
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cantly higher in obese group. Serum concentration of PTH showed posi-
tive correlation with body weight. 
4) In obese group, renal 1α-hydroxylase (Cyp27b1) mRNA level was 
upregulated and 24-hydroxylase (Cyp24) mRNA level was 
downregulated compared with control group. Cyp27b1 mRNA level cor-
related positively with serum 1,25(OH)2D concentration and Cyp24 
mRNA level showed negative correlation with serum 1,25(OH)2D con-
centration.  
5) Obese group had significantly higher mRNA levels of Vdr and 25-
hydroxylases, Cyp27a1 and Cyp2j3, than control group. 
The results from this study suggested that high fat diet-induced obesity 
influenced the expression of vitamin D metabolizing enzymes, which might 
partly explain possible mechanisms of altered vitamin D metabolism in obe-
sity. Higher concentration of serum PTH due to obesity might have induced 
abnormal regulation of serum 1,25(OH)2D concentration by stimulating re-
nal 1α-hydroxylase expression and attenuating renal 24-hydroxylase expres-
sion. Hepatic 25-hydroxylation might have been inhibited by increased se-
rum 1,25(OH)2D concentration at mRNA level. Higher mRNA expression 
of VDR in adipose tissue might suggest the possibility of enhanced 
nonclassic functions by the interaction between 1,25(OH)2D and VDR in 
adipose tissue.    
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고지방 식이로 유도한 비만이 마우스의 
비타민 D 대사 관련 효소 발현에 미치는 영향 
 
서울대학교 대학원 식품영양학과 
박 정 민 
 
비만인 사람에게서 비타민 D 결핍증 또는 부족증이 흔하게 나타나고 
그 판단 지표인 혈청 25(OH)D 농도가 낮음이 보고되고 있다. 
비만인에서의 혈청 25(OH)D 농도 저하와 관련하여, 외부 활동 감소로 
인한 햇빛으로부터의 비타민 D 합성 부족, 간에서의 25(OH)D 생성 
저해 등의 설명이 제시되어 왔으나, 아직 정확한 기전은 밝혀지지 
않았다. 본 연구에서는 고지방 식이로 유도한 비만 마우스에서 비타민 
D 대사물질 수준과 관련 효소 발현을 측정하여, 비만으로 인해 비타민 
D 대사에 이상이 일어나는지를 확인하고 그 잠재적인 기전을 
파악하고자 하였다. 4 주령의 C57BL/6 마우스를 두 군에 배정하여 
대조군은 총 식이 열량의 10%를 지방으로 공급하는 일반식이를, 
비만군은 총 식이 열량의 45%를 지방으로 공급하는 고지방식이를 
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18 주간 자유 급여하였다. 혈청 25(OH)D 농도는 군 간 차이가 
없었으나, 혈청 1,25(OH)2D 농도는 비만군에서 유의적으로 높았다. 간 
조직에서 25-hydroxylase 의 mRNA 발현은 비만군에서 세 종류의 
25-hydroxylases 모두 유의적으로 낮았다. 하지만 CYP27A1 의 
단백질 발현은 군 간에 차이가 없었다. 비만군의 신장 조직에서 1α-
hydroxylase (Cyp27b1) 의 mRNA 발현은 유의적으로 높았고, 24-
hydroxylase (Cyp24) 의 mRNA 발현은 유의적으로 낮았다. 혈청 
1,25(OH)2D 농도는 신장의 Cyp27b1 mRNA 발현 수준과 양의 
상관관계를, Cyp24 mRNA 발현 수준과는 음의 상관관계를 보였다. 
혈청 칼슘 농도는 군 간 차이가 없었으나, 혈청 PTH 농도는 비만 
마우스에서 더 높게 나타났다. 또한, 혈청 PTH 의 농도는 체중과 
유의적인 양의 상관관계를 보였다. 백색지방 조직에서는 25-
hydroxylase 인 Cyp27a1 와 Cyp2j3 의 mRNA 수준과 vitamin D 
receptor (Vdr)의 mRNA 수준이 비만군에서 더 높았다. 결론적으로, 
비타민 D 대사 관련 효소의 발현은 고지방 식이로 유도한 비만에 의해 
영향을 받았으며, 이는 비만에서의 비타민 D 대사 변화 기전을 일부 
설명할 수 있다. 비만으로 인한 PTH 증가가 혈청 1,25(OH)2D 의 높은 
농도에 기여한 것으로 보이며, 이는 비만 마우스에서 관찰된 신장 1α-
hydroxylase 의 발현 증가와 신장 24-hydroxylase 의 발현 감소에 
의한 것으로 사료된다. 비만으로 인해 비정상적으로 높아진 혈청 
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1,25(OH)2D 의 농도가 간에서의 25-hydroxylase 의 발현을 mRNA 
수준에서 낮게 하는 데에 기여했을 가능성이 있다. 비만 마우스의 
내장지방 조직에서 25-hydroxylase mRNA 와 Vdr mRNA 발현의 
증가는 지방 조직 내 국부적인 25(OH)D 생성 및 1,25(OH)2D 와 VDR 
결합에 의한 nonclassic functions 의 증가 가능성을 제시한다. 
 
주요어: 비만, 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, 간의 
25-hydroxylase, 신장의 1α-hydroxylase, 신장의 24-hydroxylase, 
고지방 식이를 섭취한 마우스 
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